Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583793 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7820321 | 0.78 | SLC22A6 (0.50) | SMN1; SMN2TDP1SLC22A6GABRR1LMNA | |
| SCHEMBL3874518 | 0.77 | — | — | |
| SCHEMBL31527767 | 0.77 | USP2 (0.48) | SMN1; SMN2MEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL300199 | 0.77 | USP2 (0.48) | SMN1; SMN2MEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13497176 | 0.77 | USP2 (0.48) | SMN1; SMN2MEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL300200 | 0.77 | USP2 (0.48) | SMN1; SMN2MEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28410409 | 0.77 | USP2 (0.48) | SMN1; SMN2MEN1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7024309 | 0.75 | — | — | |
| SCHEMBL2961393 | 0.74 | TDP1 (0.46) | SMN1; SMN2TDP1SLC22A6GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225272-B1 | PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS AS (DK) | 2015-10-21 | — | — | EP | disclosed |
| US-8470964-B2 | Peptides derived from NCAM (FGLs) | ENKAM PHARMACEUTICALS A/S (DK) | 2013-06-25 | — | — | US | disclosed |
| EP-1765861-B1 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS AS (DK) | 2012-02-15 | — | — | EP | disclosed |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | COPENHAGEN UNIVERSITY | 2011-04-28 | — | — | US | disclosed |
| EP-2225272-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | Enkam Pharmaceuticals A/S (DK) | 2010-09-08 | — | — | EP | disclosed |
| EP-1660539-B1 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS AS (DK) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009068042-A2 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLS) | ENKAM PHARMACEUTICALS A/S (DK) | 2009-06-04 | — | — | WO | disclosed |
| US-20090105149-A1 | Compounds comprising lpa | ENKAM PHARMACEUTICALS A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090074774-A1 | Fgfr binding peptides | ENKAM PHARMACEUTICALS A/S (DK) | 2009-03-19 | — | — | US | disclosed |
| US-20080226639-A1 | Heparin Binding Peptide | ENKAN PHARMACEUTICALS A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| WO-2005014623-A9 | COMPOUNDS COMPRISING LPA | — | 2006-03-23 | — | — | WO | disclosed |
| WO-2005123759-A2 | FGFR BINDING PEPTIDES | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121168-A2 | HEPARIN BINDING PEPTIDE | ENKAM PHARMACEUTICALS A/S (DK) | 2005-12-22 | — | — | WO | disclosed |
| EP-1573000-A2 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005014623-A2 | COMPOUNDS COMPRISING LPA | ENKAM PHARMACEUTICALS A/S (DK) | 2005-02-17 | — | — | WO | disclosed |
| US-20050037478-A1 | Crystal structure of glutamate racemase (MurI) | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004061097-A2 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | WO | disclosed |
| US-5041644-A | Bactericides | MERCK & CO., INC. (US) | 1991-08-20 | — | — | US | disclosed |
| EP-0073143-B1 | NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES | Ryan, James Walter (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105149-A1 | Compounds comprising lpa | FGFR1, FGFR3, FGFR2 | SMN1; SMN2 1845/4885MEN1 3282/4885CYP2D6 4827/4885 |
| US-20110098225-A1 | NOVEL PEPTIDES DERIVED FROM NCAM (FGLs) | L1CAM, FGFR1, FGFR3 | SMN1; SMN2 465/4885MEN1 2643/4885CYP2D6 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.